Rentokil Initial Share Discussion Threads

[mortal1ty] 19/10/2023 08:03

Well given this is a bond proxy with slowing growth and bond yields roofing it, in suprised this hasn't fallen a lot already. It has come catching up to do.

[smcni1968] 19/10/2023 07:50

Too bad they don't have a service for the elimination of short sellers

[babbler] 19/10/2023 07:47

Absolutely. Market completely over punishes. Now RTO have seen huge increase in bedbug work recently however. Surprised they didn't highlight that.But bedbugs have made a resurgence thanks to Britons' love of international travel leading to holidaymakers bringing the insects home with them. In fact, Rentokil alone treated 65 per cent more bed bug infestations in the second quarter of 2023 compared to the year beforeDaily mail article today

[netcurtains] 19/10/2023 07:45

Shares take for ever to rise then fall - splat - in an instant.
Its such a soul destroying game...

[ianio5691] 19/10/2023 07:35

got to be worth a punt for a quick 20% at these levels.

Can't see any reason for sell off.

[babbler] 19/10/2023 07:34

USA softening is what did the fall.

[netcurtains] 19/10/2023 07:29

18% arghhhh

when will it stop???

what has happened?

[joshuam] 19/10/2023 07:27

Can’t see any bad bit net

[netcurtains] 19/10/2023 07:25

Blimey its 17.1% now...

Can someone tell me what the problem is?
Sorry, I just can't see it..

Thanks

[netcurtains] 19/10/2023 07:22

joshuam: I'm reading the update and can you tell me (or anyone) where the bad bit is that made it fall 13%+?

Apologies if its obvious I just cannot see it.

[joshuam] 19/10/2023 07:18

Shocked this as fallen so much

[smcni1968] 13/10/2023 12:06

Trading update next Thursday

[netcurtains] 12/10/2023 09:22

Bed bugs the next plague.......

Rentokil the next AstraZeneca?

[powereddrones] 11/10/2023 18:59

What can we do?

Bedbugs are difficult to have removed. They are so small they can get inside mattresses plus folds in fabrics and clothing.

Treating an infestation in a house can cost £600 to £800 for an average three-bed house – though multiple treatments are often needed. The process is also disruptive as beds need to be stripped and wardrobes, drawers and shelves emptied with contents sealed. Occupants also must leave the property.

[netcurtains] 10/10/2023 19:28

Rentokil mentioned in the Guardian....

[smcni1968] 04/10/2023 16:54

A shorter called Spruce Point put out a very negative report on competitor Rollins saying Rentokil are doing much better in the US with Terminix

[netcurtains] 04/10/2023 13:53

From their website:

"
Entotherm is our chemical-free heat treatment used to control bed bugs and to help prevent re-infestations. The heat treatment kills all lifecycle stages of pest insects – eliminating eggs, larvae and adult insects in one treatment.
"

[netcurtains] 04/10/2023 13:25

Possibly doing well on the bed bug plague coming in from France

[netcurtains] 29/9/2023 07:57

I think, in some ways, RTO has one of the best technical short term buy signals....
But I guess these things are often wrong.

[hedgehog 100] 26/8/2023 10:33

ASHI's proposed RTO is now intended to be a DOUBLE RTO, valued at over £175M. including the £135M. Cell Therapy valuation and ASHI's shell value:-

24/08/2023 07:00 UK Regulatory (RNS & others) Ashington Innovation PLC Heads of Terms Signed for the Acquisition of Calon LSE:ASHI Ashington Innovation Plc
"Heads of Terms Signed for the Acquisition of Calon Cardio-Technology Limited, subject to the Completion of the Reverse Takeover of Cell Therapy Limited
Ashington Innovation plc (LSE: ASHI; FSE: 6FW), a special purpose acquisition company, is pleased to announce it has entered into a non-binding heads of terms agreement with Calon Cardio-Technology Limited ("Calon"), to acquire 100% of the outstanding shares in Calon in an all-share transaction. The acquisition is subject to the completion of the proposed reverse takeover of Cell Therapy Limited ("CTL") ...
Following recent discussions, on 23 August 2023 Ashington entered a non-binding heads of terms agreement with Calon for the acquisition of 100% of the issued share capital of Calon for a purchase price of GBP39 million, to be satisfied by the allotment and issue of new ordinary shares in Ashington Innovation PLC to the shareholders of Calon. ..."

[hedgehog 100] 23/8/2023 19:58

The shell company ASHI floated at 3p per share in June, market cap. £1.841M., compared to net cash of £717K., including its net IPO proceeds.

That didn't look cheap, but to its credit it has suspended (at 2.75p) for a RTO, valued at well over £100M., just two and a half months later:-


06/06/2023 08:01 UK Regulatory (RNS & others) Ashington Innovation PLC Ashington - Admission to trading on the LSE LSE:ASHI Ashington Innovation Plc

"Admission to trading on the London Stock Exchange

Ashington Innovation plc, a special purpose acquisition company ("SPAC") aiming to benefit from favourable price conditions for companies in the financial services technology (fintech) and deep technology (deep tech) sectors, is pleased to announce that its entire issued ordinary share capital, consisting of 61,397,900 ordinary shares, was admitted to the Standard Listing Segment of the Official List of the Financial Conduct Authority, and to trading on the London Stock Exchange's Main Market for listed securities at 8.00 a.m. today, under the ticker "ASHI". ...

About Ashington Innovation plc

Ashington Innovation PLC is a special purpose acquisition company (SPAC), formed with the intention of acquiring businesses operating in the technology sector, in particular the financial services technology and deep technology sectors.

The Company believes that in the increasingly fast-changing global environment there will be an abundance of opportunities to acquire existing businesses in the technology sector, and in particular businesses that possess and utilise proprietary technologies and own applicable intellectual property.

The Company is not limited to any specific geographic region in identifying its target companies. Both Jason Drummond and Jason Smart, directors of the Company, bring a wealth of experience in founding and building successful companies across a diverse range of sectors.

www.ashingtoninnovationplc.com "




17/08/2023 08:10 UK Regulatory (RNS & others) Ashington Innovation PLC Heads of Terms Signed LSE:ASHI Ashington Innovation Plc

"Heads of Terms Signed

Proposed Reverse Takeover of Cell Therapy Limited

Suspension of Listing

Conditional Acquisition of Cell Therapy Limited

Ashington Innovation (LSE:ASHI), the Special Purpose Acquisition Company (SPAC) established to acquire businesses primarily in the technology sector, is pleased to announce that the Company has entered into a non-binding term sheet (the "Term Sheet") with Cell Therapy Limited ("Cell Therapy") pursuant to which Ashington Innovation will acquire 100% of the total issued equity for GBP135 million in an all share transaction (the "Transaction"). Cell Therapy is a clinical stage biotechnology firm with a portfolio of patented cellular medicines with a lead program that successfully completed an early-stage human clinical trial in heart failure.

The Directors of Ashington Innovation consider the Transaction to represent a transformational, value enhancing transaction for shareholders, which is fully aligned with the Company's growth strategy. Cell Therapy's product and patent portfolio provides a platform to develop leading medicines, which have been validated in a human clinical trial and through granted patents in the US, UK, EU and Asia.

To fund the Transaction, Ashington Innovation will be seeking to carry out a placing of new ordinary shares to new and existing investors ("Placing") to raise funds of up to GBP3 million to finance the drug development program and working capital. As such, the Transaction is conditional, inter alia, on the completion of due diligence, definitive sale and purchase documentation, obtaining the necessary regulatory approvals from the FCA and the Takeover Panel, a successful Placing, and the passing of necessary resolutions to approve the Transaction by the shareholders of the Company at a duly convened general meeting.

Suspension of Listing

As the proposed acquisition, if it proceeds, will constitute a Reverse Takeover under the Listing Rules, the Company's ordinary shares shall be suspended pending the publication of a prospectus or an announcement that the proposed Transaction is not proceeding. Any restoration of the listing is subject to the approval of the FCA.

At this stage, there can be no guarantee that the proposed Transaction will complete nor as to the final terms of the proposed Transaction. Further announcements and updates will be made in due course.

Jason Smart, Founder of Ashington Innovation, commented: "We are delighted to have agreed a heads of terms to acquire Cell Therapy. During the past few months, we have reviewed numerous projects and believe the proposed acquisition meets our stated objective of identifying a potentially extremely valuable entity capable of sustainable development and with significant technological advantages. The directors believe that the regenerative medicine and biotechnology sector presents compelling opportunities to create value for shareholders and the proposed acquisition presents a high-quality target with an experienced and expert leadership. This is a very exciting opportunity to bring a scalable business with a strong track record to the public markets." "




Ashington Innovation (ASHI):-

[smcni1968] 23/8/2023 00:59

Quite a pullback

[smcni1968] 28/7/2023 08:33

Unfortunately their US peer Rollins dropped 9% yesterday on weaker earnings

[philanderer] 27/7/2023 23:38

Rentokil sets its high-tech sights on London’s rats as revenue rises

The FTSE 100 pest controller is using AI to tackle an age-old problem